Please login to the form below

Not currently logged in
Email:
Password:

Xgeva

This page shows the latest Xgeva news and features for those working in and with pharma, biotech and healthcare.

Amgen’s R&D chief Sean Harper retires to seek biotech post

Amgen’s R&D chief Sean Harper retires to seek biotech post

osteoporosis therapy Prolia (denosumab) and Xgeva for bone metastases, up 21% to $8610m and 14% to $452m, respectively.

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics